Page contentsCurrent version - effective from 01/06/2024Document historyRelated contentTopicsThis document provides product-specific guidance on the demonstration of the bioequivalence of Fampridine.Keywords: Bioequivalence, generics, fampridineAbbreviations:BCS Classification: Biopharmaceutics Classification SystemAUC0-t: area under the plasma concentration curve from administration to last observed concentration at time tAUC0-72: area under the plasma concentration curve from administration to last observed concentration at 72 hoursCmax: maximum plasma concentration Current version - effective from 01/06/2024 Fampridine prolonged-release tablet 10 mg product specific bioequivalence guidanceAdoptedReference Number: EMA/CHMP/39346/2023Legal effective date: 01/06/2024 English (EN) (144.86 KB - PDF)First published: 28/11/2023View Document history Fampridine prolonged-release tablet 10 mg product specific bioequivalence guidanceDraft: consultation closedConsultation dates: 22/06/2023 to 30/09/2023Reference Number: EMA/CHMP/39346/2023 English (EN) (147.05 KB - PDF)First published: 22/06/2023View Related content Product-specific bioequivalence guidanceInvestigation of bioequivalenceTopicsScientific guidelinesShare this page